Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

doi:10.1200/JCO.2014.58.1736

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jun 2015

Lee Chee Khoon, Wu Yi-Long, Ding Pei Ni, Lord Sarah J, Inoue Akira, Zhou Caicun, Mitsudomi Tetsuya, Rosell Rafael, Pavlakis Nick, Links Matthew, Gebski Val, Gralla Richard J, Yang James Chih-Hsin

Abstract excerpt

PURPOSE: We examined the impact of different epidermal growth factor receptor (EGFR) mutations and clinical characteristics on progression-free survival (PFS) in patients with advanced EGFR-mutated non-small-cell lung cancer treated with EGFR tyrosine kinase inhibitors (TKIs) as first-line therapy. PATIENTS AND METHODS: This meta-analysis included randomized trials comparing EGFR TKIs with chemotherapy. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease-Free Survival

Share to Enzyme Inhibitors

Share to ErbB Receptors

Share to Odds Ratio

Share to Protein-Tyrosine Kinases

Share to Smoking

Source

Open in PubMed

Identifiers

PMID: 25897154
DOI: 10.1200/JCO.2014.58.1736

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.PMID 25897154Read ↗

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.Semantic proximity Read ↗

Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.Semantic proximity Read ↗

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.Semantic proximity Read ↗

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.Semantic proximity Read ↗

Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.Semantic proximity Read ↗

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.Semantic proximity Read ↗

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.Semantic proximity Read ↗

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.Semantic proximity Read ↗

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?Semantic proximity Read ↗

EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.